Peter Schuck of Yale Law School has a nice Commentary in The American Lawyer (here seen via Law.com in favor of a "qualified regulatory compliance defense" to drug manufacturers' tort liability. FDA approval of a drug or device should ordinarily pre-empt "design defectd" liability, unless plaintiff can show that the manufacturer failed to fully inform the FDA of risks of which the manufacturer was or should have been aware.